1. Copyright © 2003 American Medical Association. All rights reserved.
From: Management of Venous ThromboembolismPast, Present, and Future
Arch Intern Med. 2003;163(7): doi: /archinte
Figure Legend:
Management milestones in venous thromboembolism (VTE). A timeline from approximately 1960 to the present indicates the seminal clinical trials that have influenced the use of emerging drugs for VTE prevention and treatment. HFS indicates hip fracture surgery; HITTS, heparin-induced thrombocytopenia thrombosis syndrome; LMWH, low-molecular-weight heparin; OA, oral anticoagulants; PE, pulmonary embolism; THR, total hip replacement; TKR, total knee replacement; and UFH, unfractionated heparin.
Date of download: 10/29/2017
Copyright © 2003 American Medical Association. All rights reserved.

2. Copyright © 2003 American Medical Association. All rights reserved.
From: Management of Venous ThromboembolismPast, Present, and Future
Arch Intern Med. 2003;163(7): doi: /archinte
Figure Legend:
Targeted specificity of new anticoagulants. A schematic representation of coagulation cascade components with new anticoagulants labeled to show their site of action. APC indicates activated protein C; NAPc2, nematode anticoagulant peptide c2; TF, tissue factor; and TFPI, tissue factor pathway inhibitor.
Date of download: 10/29/2017
Copyright © 2003 American Medical Association. All rights reserved.